Jaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and short bowel syndrome (SBS) with intestinal failure

Proof-of-concept studies of crofelemer for MVID and SBS planned for 2024

• Obtained rights from Washington University to develop and incorporate human HER2 directed antibodies
• Complements early pipeline of novel tunable "Knob domain" antibodies for HER2 & HER3

Jaguar planning to begin commercial launch of FDA-approved Gelclair® prescription gel for oral mucositis (also called "chemo mouth") in Q3 2024

Catherine Miller Collis was instrumental in bringing about Jaguar's recent in-license agreement for FDA-approved Gelclair^®, a protective gel for management of oral mucositis, a common, painful, and debilitating cancer treatment-related side effect